A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis

Biomed Chromatogr. 2004 Nov;18(9):723-6. doi: 10.1002/bmc.384.

Abstract

A specific, accurate and precise high-performance liquid chromatographic assay was developed for the determination of riluzole, a drug used to treat patients with amyotrophic lateral sclerosis. Samples were treated by extraction with dichloromethane followed by reversed-phase chromatography with ultraviolet detection at 260 nm. Preset validation criteria were met from 20 to 2000 ng/mL with a linear response curve. Extraction recovery of riluzole was 65-76%. The accuracy of the method was 102-103%. Intra- and inter-day coefficients of variation were in the ranges 2.8-4.9% and 1.8-9.7%. A detection limit of 5 ng/mL was found. Determination of concentrations in serum and plasma resulted in similar results below 500 ng/mL. At higher values a matrix effect cannot be excluded. This presented method can be used to monitor plasma or serum levels in ALS patients treated with riluzole.

Publication types

  • Validation Study

MeSH terms

  • Amyotrophic Lateral Sclerosis / blood*
  • Calibration
  • Chromatography, High Pressure Liquid / methods*
  • Drug Monitoring
  • Excitatory Amino Acid Antagonists / blood*
  • Reference Standards
  • Reproducibility of Results
  • Riluzole / blood*
  • Sensitivity and Specificity
  • Spectrophotometry, Ultraviolet

Substances

  • Excitatory Amino Acid Antagonists
  • Riluzole